Email Updates

Search form

You are here


Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. TDF/FTC is approved for use as oral PrEP in a handful of countries but, for maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

Sexual Health published a special issue featuring 17 articles focused on the opportunities and challenges for health service providers engaged in PrEP prescribing.

December 1, 2018
Sexual Health

The Indian Council of Medical Research (ICMR) has indicated it is planning to study the effectiveness of PrEP in high-risk groups. Those high risk groups include MSM and trans women.

November 3, 2018
Gay Star News

In Nigeria, more than 3 million people are living with HIV, but less than 400 people at the highest risk of infection are using PrEP, widely regarded as a key tool in the battle against the disease’s spread.

November 7, 2018

This post by looks at the potential role of apps in HIV prevention and treatment, particularly for youth. Dr. Lisa Hightow-Weidman, MD, MPH discusses her work at the NIH funded University of North Carolina/Emory Center for Innovative Technology (iTech) where she is developing an APP aimed at supporting PrEP use among young people at risk of HIV.

November 8, 2018
Subscribe to RSS - PrEP